Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of AVN 211 in patients with Alzheimer's disease

Trial Profile

Phase II trial of AVN 211 in patients with Alzheimer's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVN 211 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use

Most Recent Events

  • 25 Jul 2013 New trial record
  • 15 Jul 2013 This study is expected to be initiated in 2014, according to an Avineuro Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top